ATGL-1 levels increase and lipid droplets decrease in response to <i>N. parisii</i> infection. by Hala Tamim El Jarkass (16625309)

Subjects:

Scheme of g-λ model with larger values λ. by Zhanfeng Fan (20390992)

“…The findings suggest that when λ is respectively equal to 4.19, 8.57, 10, and 12.15, the peak particle velocity (PPV) of the transmitted waves is significantly close to the incident wave amplitude. Furthermore, when λ is fixed, the energy transmission coefficient increases with the incident wave amplitude but decreases with the incident wave frequency. …”

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

<i>Aedes aegypti</i> database from SAGO traps. by Jesús A. Aguilar-Durán (9931967)

Subjects:

Join-point regression analysis of the statistically significant linear increase in use of antidementia and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Significant condition. by Junxia Zhou (14381598)

Subjects:

Effects of pre-medication and warming device on systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures in dogs following pre-medication, induction and inhalant anesthesi... by Jacob P. Rastas (20642173)

Subjects:

Effects of pre-medication and warming device on heart rate (HR) assessed by pulse oximetry in dogs following pre-medication, induction and inhalant anesthesia. by Jacob P. Rastas (20642173)

Subjects:

S1 File - by Jacob P. Rastas (20642173)

Subjects:

Times to tracheal extubation, sternal recumbency and standing (minutes) following inhalant anesthesia and final rectal temperatures (°C) in each premedication-treatment group. by Jacob P. Rastas (20642173)

Subjects:

AVAcore placement. by Jacob P. Rastas (20642173)

Subjects:

Statistically significant linear increase in use of psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects: